Valley National Advisers Inc. Makes New $2.04 Million Investment in STERIS plc $STE

Valley National Advisers Inc. purchased a new stake in STERIS plc (NYSE:STE) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 8,265 shares of the medical equipment provider’s stock, valued at approximately $2,044,000.

A number of other institutional investors have also modified their holdings of STE. Northwestern Mutual Wealth Management Co. boosted its stake in STERIS by 14.0% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 2,233 shares of the medical equipment provider’s stock valued at $506,000 after acquiring an additional 274 shares during the period. Ieq Capital LLC lifted its holdings in shares of STERIS by 165.0% in the 1st quarter. Ieq Capital LLC now owns 4,627 shares of the medical equipment provider’s stock worth $1,049,000 after purchasing an additional 2,881 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of STERIS by 11.4% in the 1st quarter. BNP Paribas Financial Markets now owns 181,920 shares of the medical equipment provider’s stock worth $41,232,000 after purchasing an additional 18,640 shares during the last quarter. State of Wyoming boosted its position in STERIS by 21.9% during the 1st quarter. State of Wyoming now owns 2,377 shares of the medical equipment provider’s stock valued at $539,000 after purchasing an additional 427 shares during the period. Finally, Vident Advisory LLC grew its stake in STERIS by 45.5% during the 1st quarter. Vident Advisory LLC now owns 3,350 shares of the medical equipment provider’s stock worth $759,000 after buying an additional 1,048 shares during the last quarter. Institutional investors own 94.69% of the company’s stock.

STERIS Price Performance

Shares of STE opened at $255.29 on Friday. The firm has a market capitalization of $25.06 billion, a price-to-earnings ratio of 36.68 and a beta of 1.01. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.63 and a current ratio of 2.37. STERIS plc has a one year low of $200.98 and a one year high of $268.60. The stock’s fifty day moving average is $254.28 and its 200-day moving average is $244.59.

STERIS (NYSE:STE) last posted its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.38 by $0.09. The business had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. STERIS had a net margin of 12.07% and a return on equity of 14.43%. During the same quarter in the prior year, the company posted $2.14 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. Equities analysts anticipate that STERIS plc will post 9.08 EPS for the current year.

STERIS Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 18th. Stockholders of record on Tuesday, November 18th were issued a $0.63 dividend. The ex-dividend date was Tuesday, November 18th. This represents a $2.52 annualized dividend and a dividend yield of 1.0%. STERIS’s dividend payout ratio (DPR) is 36.21%.

Insider Activity at STERIS

In other STERIS news, VP Renato Tamaro sold 5,036 shares of the stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $257.55, for a total transaction of $1,297,021.80. Following the completion of the transaction, the vice president directly owned 5,695 shares of the company’s stock, valued at approximately $1,466,747.25. This trade represents a 46.93% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP John Adam Zangerle sold 15,000 shares of the business’s stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $265.14, for a total value of $3,977,100.00. Following the completion of the sale, the vice president directly owned 33,669 shares in the company, valued at $8,926,998.66. This represents a 30.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 25,203 shares of company stock worth $6,624,667 over the last ninety days. Insiders own 1.07% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on STE shares. Weiss Ratings reiterated a “buy (b)” rating on shares of STERIS in a research note on Tuesday, October 14th. Wall Street Zen raised shares of STERIS from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 14th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, STERIS presently has an average rating of “Moderate Buy” and an average target price of $273.50.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.